NCT05753501: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Sponsor: AbbVie. Phase: PHASE1. Conditions: Hematologic Cancer